Enanta Pharmaceuticals, Inc. (ENTA) - Q3 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Enanta Pharmaceuticals is a biotechnology company focused on discovering and developing small molecule drugs for virology and immunology. The company's primary revenue source is royalties from its collaboration with AbbVie regarding the HCV treatment MAVYRET/MAVIRET. The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q3 2026 (3 Months) | Q3 2025 (3 Months) | YTD 2026 (9 Months) | YTD 2025 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $14.4 million | $18.3 million | $50.1 million | $50.2 million |
| Net Loss | $(19.5) million | $(18.3) million | $(44.5) million | $(63.2) million |
| Net Loss Per Share | $(0.67) | $(0.85) | $(1.54) | $(2.96) |
| R&D Expenses | $22.1 million | $27.2 million | $62.4 million | $82.9 million |
| G&A Expenses | $9.5 million | $10.0 million | $28.0 million | $34.2 million |
| Cash & Investments | $211.5 million (as of June 30, 2026) | |||
| Operating Cash Flow (YTD) | $(28.8) million | $(12.8) million |
Material Changes vs. Prior Period
- Revenue Decline: Q3 revenue decreased by $4.0 million (22%) compared to Q3 2025, primarily due to lower reported HCV sales by AbbVie. YTD revenue remained relatively flat.
- Expense Reduction: Total operating expenses decreased by $5.6 million in Q3 and $26.7 million YTD. R&D expenses dropped significantly ($5.1M in Q3, $20.5M YTD) due to the timing of clinical trials in the RSV program, partially offset by increased spending on immunology programs (KIT, STAT6, MRGPRX2).
- Improved Net Loss: Net loss narrowed to $19.5 million in Q3 from $18.3 million in Q3 2025, and improved significantly on a YTD basis ($44.5M vs $63.2M), driven by lower operating expenses and a one-time $33.8M tax refund received in April 2025 that is not recurring.
- Interest Expense Increase: Interest expense rose to $4.1 million in Q3 (from $1.6M) and $10.5 million YTD (from $5.3M) due to higher forecasted royalties triggering increased imputed interest on the OMERS royalty sale liability.
- Capital Raise: In October 2025, the company completed a public offering raising approximately $70 million net of costs, significantly bolstering liquidity.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects current cash, cash equivalents, and marketable securities ($211.5 million) combined with retained royalty cash flows to fund operations into fiscal 2029.
- ATM Facility: On July 2, 2026, the company entered an Open Market Sale Agreement to sell up to $75.0 million of common stock via an at-the-market facility.
- Clinical Pipeline:
- RSV: Plans to initiate the registrational Phase 2b/3 RESOLVE trial in high-risk adults in Q4 2026. The pediatric LOTUS trial began dosing in Q3 2026.
- Immunology: Phase 1 trial for KIT inhibitor EDP-978 began in April 2026; topline data expected Q4 2026. IND filing for STAT6 inhibitor EPS-3903 is targeted for H2 2026.
- Legal Contingency: The Federal Circuit affirmed the invalidity of the Company's '953 Patent regarding Pfizer's Paxlovid in June 2026. The Company has petitioned for rehearing, with a decision expected by September 2026. A separate infringement suit in the European Union (UPC) regarding the '265 Patent has a hearing scheduled for September 29, 2026.
- Royalty Sale Liability: The company retains 45.5% of royalties from MAVYRET/MAVIRET sales through June 2032, with 54.5% paid to OMERS. The liability balance was $125.1 million as of June 30, 2026.
Investor Verification Checklist
- Cash Runway: Verify the sustainability of the $211.5 million cash position against the projected burn rate, considering the upcoming Phase 3 RSV trials.
- AbbVie Sales Trends: Monitor AbbVie's MAVYRET/MAVIRET sales reports, as Enanta's revenue is directly tied to these figures and the tiered royalty structure.
- Legal Outcomes: Track the Federal Circuit rehearing decision (expected Sept 2026) and the UPC hearing (Sept 2026) regarding the Pfizer patent litigation, as a loss could impact future revenue potential or require licensing fees.
- OMERS Liability: Review the impact of the $125 million royalty sale liability and the associated imputed interest expense on future net loss calculations.
- ATM Utilization: Monitor if and when the company utilizes the new $75 million ATM facility, which could lead to shareholder dilution.